The Ethics of Growth-Promoting Pharmaceuticals for Achondroplasia

Abstract

In 2021, vosoritide became the first pharmaceutical approved to treat the pathophysiology of achondroplastic dwarfism. It has generated significant ethical debate. Proponents emphasize its potential to improve quality of life and functional independence, whereas critics raise concerns about pathologizing human variation, eroding cultural identity, and limiting children's autonomy. The drug has an extremely high cost (approximately $300,000 USD per year per patient) and is non-lifesaving, further provoking questions of distributive justice and public funding. This paper examines the key ethical issues surrounding vosoritide, including the distinction between its medical and social benefits, its potential impact on identity, the inclusion of disability communities in study design, the limits of parental decision-making, and the justification for public reimbursement. We argue that ethical evaluation requires robust empirical evidence on both medical and quality-of-life outcomes, inclusion of disability communities in the research process, and long-term psychosocial follow-up and mandated data sharing of treated children.